Gen-Probe Inc. (GPRO) said Tuesday that the US Food and Drug Administration has cleared for marketing Prodesse's ProParaflu+ assay, a molecular test that detects and differentiates parainfluenza 1, 2 and 3 viruses, which cause lower respiratory tract infections. Prodesse is a wholly-owned subsidiary of Gen-Probe.
The ProParaflu+ assay uses real-time RT- polymerase chain reaction to identify the parainfluenza 1, 2 and 3 viruses from nasal swabs. The assay uses the same internal control as Prodesse's other tests for respiratory infectious diseases, so a single nucleic acid extract can be tested with any combination of those products.
For comments and feedback: editorial@rttnews.com